<DOC>
	<DOC>NCT00231166</DOC>
	<brief_summary>The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapsed after receiving prior treatment.</brief_summary>
	<brief_title>Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Clinical Diagnosis of MM requiring treatment Refractory or Relapsed Disease At least one prior treatment regimen Male or Female &gt;18 years of age Prior Allogeneic bone marrow transplant (prior autologous transplant allowed) Intracranial disease or epidural disease Clinically significant cardiac dysfunction or other significant organ dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>dose-finding</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>